Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
ORGANIZATION
Re-Pricing Rules Need Drastic Overhaul, Possible Abolishment Should Be Discussed for Z2: FPMAJ
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) issued a report on June 10, prodding the government to drastically overhaul re-pricing rules for big-selling drugs and review the so-called “Z2” price cut for off-patent brand-name drugs including an option…
To read the full story
Related Article
- FPMAJ Report Warns of Repercussions from Sovaldi Price Slash
June 14, 2016
- Reimbursement Prices Kept Unchanged for Over 20% of Drugs: FPMAJ Survey
June 13, 2016
- FPMAJ Wants to Avoid Narrowing-Down of Premium-Eligible Products: Kamoya
June 13, 2016
- FPMAJ Drug Pricing Affairs Chief Lashes Out at Proposed Out-of-Cycle Re-Pricing
June 13, 2016
- Gist of FY2016 Drug Pricing Reform
December 25, 2015
ORGANIZATION
- Pharma Urges Drug Security, Demands 8.5% Price Hike: LDP Hearing
October 30, 2026
- Pharma Labor Group Seeks Political Push for Price Hikes, Fair Cost Sharing
October 30, 2026
- UA Zensen Targets 6% Wage Hike Demand for 2027
October 28, 2026
- JaDHA Keen to Grab Chuikyo Seat to Speed Reimbursement for Digital Health
October 27, 2026
- FPMAJ Urges Member Groups to Share Government PHP Security Alert
October 26, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…